Logo image of GOSS

GOSSAMER BIO INC (GOSS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:GOSS - US38341P1021 - Common Stock

3.27 USD
+0.09 (+2.83%)
Last: 11/25/2025, 8:00:01 PM
3.12 USD
-0.15 (-4.59%)
Pre-Market: 11/26/2025, 4:37:27 AM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to GOSS. GOSS was compared to 533 industry peers in the Biotechnology industry. GOSS has a bad profitability rating. Also its financial health evaluation is rather negative. GOSS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GOSS has reported negative net income.
In the past year GOSS has reported a negative cash flow from operations.
In the past 5 years GOSS always reported negative net income.
GOSS had a negative operating cash flow in each of the past 5 years.
GOSS Yearly Net Income VS EBIT VS OCF VS FCFGOSS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of GOSS (-74.77%) is worse than 63.23% of its industry peers.
Industry RankSector Rank
ROA -74.77%
ROE N/A
ROIC N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
GOSS Yearly ROA, ROE, ROICGOSS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 0 0 0 0 0 0 0 0 0 0

1.3 Margins

GOSS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GOSS Yearly Profit, Operating, Gross MarginsGOSS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

More info and screens

3

2. Health

2.1 Basic Checks

GOSS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, GOSS has more shares outstanding
The number of shares outstanding for GOSS has been increased compared to 5 years ago.
The debt/assets ratio for GOSS has been reduced compared to a year ago.
GOSS Yearly Shares OutstandingGOSS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
GOSS Yearly Total Debt VS Total AssetsGOSS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

GOSS has an Altman-Z score of -9.18. This is a bad value and indicates that GOSS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of GOSS (-9.18) is worse than 70.54% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.18
ROIC/WACCN/A
WACC8.33%
GOSS Yearly LT Debt VS Equity VS FCFGOSS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

GOSS has a Current Ratio of 3.28. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 3.28, GOSS is not doing good in the industry: 60.60% of the companies in the same industry are doing better.
GOSS has a Quick Ratio of 3.28. This indicates that GOSS is financially healthy and has no problem in meeting its short term obligations.
GOSS has a Quick ratio (3.28) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.28
Quick Ratio 3.28
GOSS Yearly Current Assets VS Current LiabilitesGOSS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

GOSS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.63%.
Looking at the last year, GOSS shows a very negative growth in Revenue. The Revenue has decreased by -58.17% in the last year.
EPS 1Y (TTM)-115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)-58.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.23%

3.2 Future

The Earnings Per Share is expected to grow by 35.39% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 30.84% on average over the next years. This is a very strong growth
EPS Next Y-164.76%
EPS Next 2Y-41.54%
EPS Next 3Y3.16%
EPS Next 5Y35.39%
Revenue Next Year-66.84%
Revenue Next 2Y-37.95%
Revenue Next 3Y3.39%
Revenue Next 5Y30.84%

3.3 Evolution

GOSS Yearly Revenue VS EstimatesGOSS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
GOSS Yearly EPS VS EstimatesGOSS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

GOSS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year GOSS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GOSS Price Earnings VS Forward Price EarningsGOSS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GOSS Per share dataGOSS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.54%
EPS Next 3Y3.16%

More info and screens

0

5. Dividend

5.1 Amount

GOSS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GOSSAMER BIO INC

NASDAQ:GOSS (11/25/2025, 8:00:01 PM)

Premarket: 3.12 -0.15 (-4.59%)

3.27

+0.09 (+2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)03-11 2026-03-11/amc
Inst Owners78.19%
Inst Owner Change1.7%
Ins Owners0.77%
Ins Owner Change7.57%
Market Cap751.71M
Revenue(TTM)44.05M
Net Income(TTM)-156.13M
Analysts84
Price Target9.62 (194.19%)
Short Float %11.29%
Short Ratio6.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.3%
Min EPS beat(2)-7.37%
Max EPS beat(2)7.97%
EPS beat(4)3
Avg EPS beat(4)7.61%
Min EPS beat(4)-7.37%
Max EPS beat(4)16.34%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.2%
EPS beat(16)12
Avg EPS beat(16)4.72%
Revenue beat(2)2
Avg Revenue beat(2)132.73%
Min Revenue beat(2)105.89%
Max Revenue beat(2)159.58%
Revenue beat(4)4
Avg Revenue beat(4)109.59%
Min Revenue beat(4)34.54%
Max Revenue beat(4)159.58%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.76%
PT rev (3m)21.66%
EPS NQ rev (1m)-16.84%
EPS NQ rev (3m)-27.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.5%
Revenue NQ rev (1m)-30%
Revenue NQ rev (3m)-28.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 17.06
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.69
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS0.19
BVpS-0.36
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-53.25%
ROA(5y)-54.59%
ROE(3y)-791.28%
ROE(5y)-528.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.28
Quick Ratio 3.28
Altman-Z -9.18
F-Score0
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)7.47%
Cap/Depr(5y)43.57%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-164.76%
EPS Next 2Y-41.54%
EPS Next 3Y3.16%
EPS Next 5Y35.39%
Revenue 1Y (TTM)-58.17%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.23%
Revenue Next Year-66.84%
Revenue Next 2Y-37.95%
Revenue Next 3Y3.39%
Revenue Next 5Y30.84%
EBIT growth 1Y-143.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-126.75%
EBIT Next 3Y31.35%
EBIT Next 5Y34.99%
FCF growth 1Y8.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.67%
OCF growth 3YN/A
OCF growth 5YN/A

GOSSAMER BIO INC / GOSS FAQ

What is the fundamental rating for GOSS stock?

ChartMill assigns a fundamental rating of 2 / 10 to GOSS.


Can you provide the valuation status for GOSSAMER BIO INC?

ChartMill assigns a valuation rating of 0 / 10 to GOSSAMER BIO INC (GOSS). This can be considered as Overvalued.


What is the profitability of GOSS stock?

GOSSAMER BIO INC (GOSS) has a profitability rating of 0 / 10.


How financially healthy is GOSSAMER BIO INC?

The financial health rating of GOSSAMER BIO INC (GOSS) is 3 / 10.